LMR Partners LLP Buys Shares of 10,000 Guardant Health, Inc. (NASDAQ:GH)

LMR Partners LLP purchased a new position in shares of Guardant Health, Inc. (NASDAQ:GH) in the 3rd quarter, HoldingsChannel.com reports. The firm purchased 10,000 shares of the company’s stock, valued at approximately $229,000.

Other institutional investors have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in Guardant Health by 21.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company’s stock worth $102,000 after acquiring an additional 796 shares in the last quarter. JNBA Financial Advisors acquired a new stake in shares of Guardant Health during the third quarter worth about $26,000. Ashton Thomas Securities LLC purchased a new position in shares of Guardant Health in the third quarter valued at approximately $34,000. Quarry LP acquired a new position in shares of Guardant Health in the second quarter valued at approximately $44,000. Finally, Green Alpha Advisors LLC increased its stake in Guardant Health by 23.6% during the 3rd quarter. Green Alpha Advisors LLC now owns 8,782 shares of the company’s stock worth $201,000 after buying an additional 1,674 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Guardant Health Stock Performance

NASDAQ GH opened at $30.68 on Thursday. The firm’s fifty day moving average price is $24.00 and its 200 day moving average price is $26.71. Guardant Health, Inc. has a 12 month low of $15.81 and a 12 month high of $37.04. The company has a debt-to-equity ratio of 16.70, a current ratio of 6.22 and a quick ratio of 5.85. The company has a market capitalization of $3.79 billion, a price-to-earnings ratio of -7.24 and a beta of 1.11.

Guardant Health (NASDAQ:GH) last posted its earnings results on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). The firm had revenue of $191.48 million for the quarter, compared to analyst estimates of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The firm’s revenue for the quarter was up 33.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.73) EPS. On average, sell-side analysts expect that Guardant Health, Inc. will post -3.38 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on GH shares. JPMorgan Chase & Co. raised their price target on shares of Guardant Health from $48.00 to $50.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Leerink Partners decreased their target price on Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. The Goldman Sachs Group boosted their target price on Guardant Health from $32.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. UBS Group increased their price target on Guardant Health from $32.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, August 21st. Finally, TD Cowen boosted their price objective on Guardant Health from $41.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Guardant Health has a consensus rating of “Moderate Buy” and an average price target of $40.60.

Insider Buying and Selling at Guardant Health

In other news, Director Meghan V. Joyce sold 2,896 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total transaction of $86,590.40. Following the completion of the sale, the director now owns 7,648 shares in the company, valued at approximately $228,675.20. This represents a 27.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 5.50% of the stock is owned by company insiders.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.